JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lin, Y. S.
Right arrow Articles by Modi, N. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, Y. S.
Right arrow Articles by Modi, N. B.

Vol. 288, Issue 1, 371-378, January 1999

Preclinical Pharmacokinetics, Interspecies Scaling, and Tissue Distribution of a Humanized Monoclonal Antibody against Vascular Endothelial Growth Factor

Yvonne S. Lin, Cindy Nguyen, Jose-Luis Mendoza, Enrique Escandon, David Fei, Y. Gloria Meng and Nishit B. Modi1

Departments of Pharmacokinetics and Metabolism (Y.S.L., C.N., J.-L.M., E.E., N.B.M.), BioAnalytical Methods Development (D.F.), and Research Immunochemistry (Y.G.M.), Genentech, Inc., South San Francisco, California

Vascular endothelial growth factor (VEGF) plays a crucial role in angiogenesis and in pathological processes such as tumor growth, rheumatoid arthritis, and ocular neovascularization. A recombinant humanized monoclonal antibody (rhuMAb), rhuMAb VEGF, has been developed to inhibit the effects of VEGF in the treatment of solid tumors. Intravenous and s.c. pharmacokinetic studies were conducted in mice, rats, and cynomolgus monkeys. In addition, the tissue distribution of i.v. 125I-rhuMAb VEGF was investigated in rabbits. At a dose of approximately 10 mg/kg, the clearance of rhuMAb VEGF from the serum was 15.7 ml/day/kg in mice, 4.83 ml/day/kg in rats, and 5.59 ml/day/kg in cynomolgus monkeys, and the terminal half-life ranged from 6 to 12 days in all species. After s.c. administration, rhuMAb VEGF had a bioavailability of 69% in rats and 100% in mice and cynomolgus monkeys. Pharmacokinetic data in mice, rats, and cynomolgus monkeys were used to predict the pharmacokinetics of rhuMAb VEGF using allometric scaling in humans. The predicted serum clearance of rhuMAb VEGF in humans was 2.4 ml/day/kg and the terminal half-life was 12 days. Two hours after i.v. bolus administration of 125I-rhuMAb VEGF in rabbits, trichloroacetic acid-precipitable radioactivity was noted primarily in the plasma, with lesser amounts in highly perfused tissues such as kidneys, testes, spleen, heart, and lungs. At 48 h after dosing, trichloroacetic acid-precipitable radioactivity was noted in plasma with minimal distribution to testes, bladder, heart, lungs, and kidneys. Tissue distribution and pharmacokinetic data indicate that rhuMAb VEGF is cleared slowly and distributes to specific sites in the body.

0022-3565/99/2881-0371$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 IOVSHome page
B. Avci, R. Avci, U. U. Inan, and B. Kaderli
Comparative Evaluation of Apoptotic Activity in Photoreceptor Cells after Intravitreal Injection of Bevacizumab and Pegaptanib Sodium in Rabbits
Invest. Ophthalmol. Vis. Sci., July 1, 2009; 50(7): 3438 - 3446.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. K. Chang, I. Rizvi, N. Solban, and T. Hasan
In vivo Optical Molecular Imaging of Vascular Endothelial Growth Factor for Monitoring Cancer Treatment
Clin. Cancer Res., July 1, 2008; 14(13): 4146 - 4153.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Chen, C. Su, Q. Lu, W. Shi, Q. Zhang, X. Wang, J. Long, Q. Yang, L. Li, X. Jia, et al.
Generation of adenovirus-mediated anti-CD20 antibody and its effect on B-cell deletion in mice and nonhuman primate cynomolgus monkey
Mol. Cancer Ther., June 1, 2008; 7(6): 1562 - 1568.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. M.W. Verheul, M. P.J. Lolkema, D. Z. Qian, Y. H.A. Hilkes, E. Liapi, J.-W. N. Akkerman, R. Pili, and E. E. Voest
Platelets Take Up the Monoclonal Antibody Bevacizumab
Clin. Cancer Res., September 15, 2007; 13(18): 5341 - 5347.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
W. B. Nagengast, E. G. de Vries, G. A. Hospers, N. H. Mulder, J. R. de Jong, H. Hollema, A. H. Brouwers, G. A. van Dongen, L. R. Perk, and M. N. Lub-de Hooge
In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor Xenograft
J. Nucl. Med., August 1, 2007; 48(8): 1313 - 1319.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. L. Muldoon, C. Soussain, K. Jahnke, C. Johanson, T. Siegal, Q. R. Smith, W. A. Hall, K. Hynynen, P. D. Senter, D. M. Peereboom, et al.
Chemotherapy Delivery Issues in Central Nervous System Malignancy: A Reality Check
J. Clin. Oncol., June 1, 2007; 25(16): 2295 - 2305.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
H. D. Sun, M. Malabunga, J. R. Tonra, R. DiRenzo, F. E. Carrick, H. Zheng, H.-R. Berthoud, O. P. McGuinness, J. Shen, P. Bohlen, et al.
Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys
Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E964 - E976.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
W. F. Dall'Acqua, P. A. Kiener, and H. Wu
Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)
J. Biol. Chem., August 18, 2006; 281(33): 23514 - 23524.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. J. Lammerts van Bueren, W. K. Bleeker, H. O. Bogh, M. Houtkamp, J. Schuurman, J. G.J. van de Winkel, and P. W.H.I. Parren
Effect of Target Dynamics on Pharmacokinetics of a Novel Therapeutic Antibody against the Epidermal Growth Factor Receptor: Implications for the Mechanisms of Action.
Cancer Res., August 1, 2006; 66(15): 7630 - 7638.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
M Milano and O Guerin
Recent advances in targeted therapies for colorectal cancer
Journal of Oncology Pharmacy Practice, June 1, 2006; 12(2): 69 - 73.
[Abstract] [PDF]

Home page
 International Journal of ToxicologyHome page
J. Gaudreault, V. Shiu, A. Bricarello, B. J. Christian, C. L. Zuch, and B. Mounho
Concomitant Administration of Bevacizumab, Irinotecan, 5-Fluorouracil, and Leucovorin: Nonclinical Safety and Pharmacokinetics
International Journal of Toxicology, September 1, 2005; 24(5): 357 - 363.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Montet, V. Ntziachristos, J. Grimm, and R. Weissleder
Tomographic Fluorescence Mapping of Tumor Targets
Cancer Res., July 15, 2005; 65(14): 6330 - 6336.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S. D Zondor and P. J Medina
Bevacizumab: An Angiogenesis Inhibitor with Efficacy in Colorectal and Other Malignancies
Ann. Pharmacother., July 1, 2004; 38(7): 1258 - 1264.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
H. X. Chen
Expanding the Clinical Development of Bevacizumab
Oncologist, June 1, 2004; 9(suppl_1): 27 - 35.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
E. Bergsland and M. N. Dickler
Maximizing the Potential of Bevacizumab in Cancer Treatment
Oncologist, June 1, 2004; 9(suppl_1): 36 - 42.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. Holash, S. Davis, N. Papadopoulos, S. D. Croll, L. Ho, M. Russell, P. Boland, R. Leidich, D. Hylton, E. Burova, et al.
VEGF-Trap: A VEGF blocker with potent antitumor effects
PNAS, August 20, 2002; 99(17): 11393 - 11398.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. P. Khor, K. McCarthy, M. DuPont, K. Murray, and G. Timony
Pharmacokinetics, Pharmacodynamics, Allometry, and Dose Selection of rPSGL-Ig for Phase I Trial
J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 618 - 624.
[Abstract] [Full Text]

eLetters:

Read all eLetters

Immunogenicity assessment
Mauricio Maia
JPET Online, 7 Jul 2000 [Full text]
Response to letter from Mauricio Maia
Nishit B. Modi
JPET Online, 7 Jul 2000 [Full text]

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.